相关实验视频

Updated: Jan 10, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

第三代EGFR-TKI结合化疗在高级非小细胞肺癌:一个现实世界的研究

YuQin Jiang¹, Qi Liang¹, Yuting Zhu¹

¹The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.

|November 29, 2025

概括

第三代表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKIs) 与化疗相结合,对晚期EGFR突变非小细胞肺癌 (NSCLC) 显示出显著的生存益处. 这项现实研究证实了有利的客观反应率和无进展生存益处.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

第三代EGFR-TKIs加化学疗法比EGFR突变NSCLC的单疗法更有前途.
现实世界的数据对于验证不同患者群体的临床试验结果至关重要.

研究的目的:

评估第一线第三代EGFR-TKIs与化学治疗相结合的先进EGFR突变NSCLC的现实有效性,安全性和进展模式.
在与化疗结合使用时,比较不同第三代EGFR-TKI的结果.

主要方法:

观察性,回顾性,单中心研究.
招募了382名患有先进EGFR突变NSCLC的患者,接受一线第三代EGFR-TKI以及基于的化疗.
主要终点:无进展生存率 (PFS);次要终点:整体生存率 (OS),客观反应率 (ORR),疾病控制率 (DCR) 和不良事件 (AE).

主要成果:

中位数PFS: 30.9个月;中位数OS: 53.9个月.
整体ORR: 76.4%; DCR: 98.2%. 总体ORR: 76.4%; 总体DCR: 98.2% .
在IPTW之后,不同第三代EGFR-TKI之间没有观察到PFS或AE的统计学上显著差异.

结论:

用第三代EGFR-TKIs和基于pemetrexed的化疗进行一线联合治疗,在晚期EGFR突变NSCLC中提供了有利的ORR和PFS益处.
这种组合策略在现实环境中是一个可行的治疗选择.
使用的第三代EGFR-TKI并没有显著影响本分析的结果.

关键词:

欧洲农业基金m 欧洲农业基金m 这是一个先进的NSCLCLC.基于的化学疗法.现实世界的世界.第三代EGFR技术技能.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...